Search
forLearn
5 / 801 resultslearn Sodium PCA
learn zinc PCA
learn ACETYL TETRAPEPTIDE-2
learn Selenium AAC
Research
5 / 1000+ resultsresearch Development and sensory analysis of shampoo for curly hair
The shampoo effectively defines and models curls while reducing frizz and volume.
research Effective treatment of skin and metabolic manifestations of hyperandrogenism: a comprehensive improvement of quality of life
Combined oral contraceptives improve skin, hormone levels, and quality of life in women with PCOS.
research Regaining Control Over Cancer: A Health Communication Initiative Documenting Complementary and Alternative Medicine Use Among Cancer Patients and Survivors
Patients should discuss complementary medicine use with doctors to improve health outcomes.
research Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
research Photoacoustic imaging for prostate brachytherapy
Photoacoustic imaging can detect prostate brachytherapy seeds better with enhanced contrast methods, but depth limits remain.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.